Logo
Neuren Pharmaceuticals

Jon Pilcher interviewed by Stephen Mayne from Intelligent Investor

Jon Pilcher sat down with Stephen Mayne from Intelligent Investor to talk through where things stand for Neuren - from the EU regulatory turnaround for DAYBU® to how the company is funding the next chapter of its pipeline.

Neuren Pharmaceuticals: The Next Chapter - Intelligent Investor

Note: This content is hosted on Intelligent Investor and access is subject to their platform policies.


0

likes

0

questions

0

company answers

Ask a question


Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.

Investor Q&As

Start the conversation

Ask Neuren Pharmaceuticals a question about this update.